U.S. inspectors documented egregious conditions at two Chinese factories making key components for compounded GLP-1 drugs popular in America, including black mold on equipment and “gross contamination” on floors at one plant. The inspectors caught employees trying to hide paperwork and furtively pouring out product samples at that plant and evidence of bogus documentation at the other, according to reports obtained under a Freedom of Information Act request. The two companies manufactured semaglutide and tirzepatide — the active ingredients in weight-loss blockbusters from Novo Nordisk A/S and Eli Lilly & Co. — for custom-made versions that aren’t approved for sale…